Compare MQ & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | NVAX |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | United States |
| Employees | 938 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2021 | 1996 |
| Metric | MQ | NVAX |
|---|---|---|
| Price | $4.37 | $8.07 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 9 |
| Target Price | $5.36 | ★ $11.33 |
| AVG Volume (30 Days) | 2.6M | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | $624,884,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $16.36 | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | 23.25 | ★ 64.69 |
| 52 Week Low | $3.70 | $5.80 |
| 52 Week High | $7.04 | $11.85 |
| Indicator | MQ | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 39.81 |
| Support Level | $3.84 | $8.01 |
| Resistance Level | $4.46 | $8.45 |
| Average True Range (ATR) | 0.14 | 0.34 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 75.52 | 8.73 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.